US9067888, 33

ID: ALA3673434

Chembl Id: CHEMBL3673434

Cas Number: 2751721-40-9

PubChem CID: 53373586

Max Phase: Preclinical

Molecular Formula: C21H24FN3O3

Molecular Weight: 385.44

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  COc1cc(F)ccc1-c1ccnc(NC(=O)[C@H]2CCC[C@@H](NC(C)=O)C2)c1

Standard InChI:  InChI=1S/C21H24FN3O3/c1-13(26)24-17-5-3-4-15(10-17)21(27)25-20-11-14(8-9-23-20)18-7-6-16(22)12-19(18)28-2/h6-9,11-12,15,17H,3-5,10H2,1-2H3,(H,24,26)(H,23,25,27)/t15-,17+/m0/s1

Standard InChI Key:  QNWXRLPZIFMTBK-DOTOQJQBSA-N

Alternative Forms

1. Parent:

   

   ALA3673434

   (1S,3R)-3-acetamido-N-[4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl]cyclohexane-1-carboxamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 385.44

Molecular Weight (Monoisotopic): 385.1802

AlogP: 3.53

#Rotatable Bonds: 5

Polar Surface Area: 80.32

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.00

CX Basic pKa: 3.71

CX LogP: 2.66

CX LogD: 2.66

Aromatic Rings: 2

Heavy Atoms: 28

QED Weighted: 0.83

Np Likeness Score: -1.02

References

1.  (2015)  Inhibitors of protein kinases, 

2. Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A..  (2016)  Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.,  59  (19): [PMID:27171036] [10.1021/acs.jmedchem.6b00150]

3. Barlaam B,Casella R,Cidado J,Cook C,De Savi C,Dishington A,Donald CS,Drew L,Ferguson AD,Ferguson D,Glossop S,Grebe T,Gu C,Hande S,Hawkins J,Hird AW,Holmes J,Horstick J,Jiang Y,Lamb ML,McGuire TM,Moore JE,O'Connell N,Pike A,Pike KG,Proia T,Roberts B,San Martin M,Sarkar U,Shao W,Stead D,Sumner N,Thakur K,Vasbinder MM,Varnes JG,Wang J,Wang L,Wu D,Wu L,Yang B,Yao T.  (2020)  Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.,  63  (24): [PMID:33306391] [10.1021/acs.jmedchem.0c01754]

4. Huang Z, Wang T, Wang C, Fan Y..  (2022)  CDK9 inhibitors in cancer research.,  13  (6.0): [PMID:35814933] [10.1039/d2md00040g]

5. Xu Z, Zhang B, Liu Z, Gou S..  (2022)  Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors.,  244  [PMID:36332552] [10.1016/j.ejmech.2022.114875]

Source

Source(2):

• Scientific Literature
• BindingDB Database